Research advances of obinutuzumab in the treatment of membranous nephropathy
Membranous nephropathy （MN） is a common cause of adult nephrotic syndrome. Rituximab, a type Ⅰ anti-CD20 monoclonal antibody, is an effective treatment of MN. However, its response rate is merely 60% during a follow-up period of up to 24 months. Obinutuzumab is a type Ⅱ humanized anti-CD20 monoclona...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Book |
| Published: |
Editorial Department of Journal of Clinical Nephrology,
2024-01-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|